PURPOSE: To evaluate the safety and performance of a recently developed expanded @entity736 (ePTFE)-covered @entity5648 stent-graft to create @entity5273 ( @entity5273 ) in @entity1 with portal @entity101 and related complications. MATERIALS AND METHODS: The ePTFE-covered @entity5648 stent-graft was used to create @entity5273 in 16 @entity1 with recurrent @entity548 (n = 13) or refractory ascites (n = 3). Follow-up was performed with duplex ultrasonography, clinical assessment, and venography at 6 months. Technical success and portosystemic pressure gradients (PPGs) before and after stent-graft implantation and at follow-up were assessed. Two @entity1 died during follow-up. Histopathologic follow-up data were available for one @entity1 at autopsy and for the other after liver transplantation. RESULTS: The implantation technical success rate was 100%. Mean (+/- SD) PPG was reduced from 24 mm Hg +/- 5 to 9 mm Hg +/- 2. Histopathologic analysis of the explanted endoprostheses revealed no inflammatory response or @entity8233 formation. The venographic follow-up data available for 10 @entity1 demonstrated 100% in-graft patency (mean follow-up, 289 days +/- 26). Revisions with implantation of a new ePTFE-covered @entity5648 stent-graft or another commercially available stent in 10 @entity1 were necessary because of @entity99 above the grafted portion and/or relative diameter mismatch causing @entity5273 . CONCLUSION: The ePTFE-covered @entity5648 stent-graft was used successfully to create @entity5273 and has the potential to prolong @entity5273 patency upon complete coverage to the hepatocaval junction.

Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a @entity736 -covered XXXX endoprosthesis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity548 :: ('MESH:D006470', 'Disease') :: ['variceal bleeding'] @entity5273 :: ('MESH:C562830', 'Disease') :: ['TIPS dysfunction', 'TIPS', 'transjugular intrahepatic portosystemic shunt'] @entity736 :: ('CHEBI:53251', 'Chemical') :: ['polytetrafluoroethylene'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic vein stenosis'] @entity5648 :: ('MESH:C013616', 'Chemical') :: ['nitinol'] @entity8233 :: ('MESH:D058426', 'Disease') :: ['neointima']
@entity5648 :: (MESH:C013616,Chemical) :: ['nitinol']
